Venous Thromboembolism in Patients with Heart Failure.
Venous thromboembolism
anticoagulation
antithrombotic prophylaxis
epidemiology
heart failure
pathophysiology
prognosis
pulmonary embolism
treatment
Journal
Current pharmaceutical design
ISSN: 1873-4286
Titre abrégé: Curr Pharm Des
Pays: United Arab Emirates
ID NLM: 9602487
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
03
2021
accepted:
02
07
2021
pubmed:
31
8
2021
medline:
7
4
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Heart failure (HF) and venous thromboembolism (VTE) are common clinical entities, closely interrelated, sharing multiple pathophysiological mechanisms. Their co-incidence is associated with further worsening of the prognosis of one another. Despite their frequent co-existence, important clinical questions still remain unanswered. The risk of VTE especially in chronic HF patients appears to vary widely in clinical studies, while the VTE-associated risk in HF patients is still not well determined and cannot be accurately predicted. Although scientific guidelines recommend venous thromboprophylaxis in patients hospitalized with an acute HF syndrome, venous thromboprophylaxis has not been studied adequately in prospective trials in ambulatory HF patients. In the present review, we aimed to summarize the current knowledge on the epidemiology of VTE and HF, the risk prediction for VTE occurrence in HF patients, the impact on patient outcome, and the need for anticoagulation in certain HF subgroups to improve prognosis, while we sought to identify gaps in knowledge that need to be addressed in the future.
Identifiants
pubmed: 34459379
pii: CPD-EPUB-117546
doi: 10.2174/1381612827666210830102419
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
512-520Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.